Annual Securities Report — FY2025
What BrightPath Biotherapeutics Co.,Ltd. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-25View the original on EDINET
How much it says
43Thin
What moved here
11named for the first time
Its own wording
35terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The filing states that during the fiscal year, the company invested funds to prepare for the start of BP2202’s U.S. clinical trials, secured funding through the exercise of stock acquisition rights and other means, and advanced R&D. Revenue came from items including upfront fees related to patent licenses, while operating loss and net loss continued.
Komori's summary of this document, not the document's own words.43Thin
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
38
Thin
52
Typical
75
Very detailed
0
Almost nothing
0
Almost nothing
55
Typical
31
Thin
7
Almost nothing
79
Very detailed
60
Detailed
R&D spend10億円Money spent making new things.
Cash left over-14億円Cash from the business, less what went into equipment.
Spent on equipment9百万円Plants, machines — things meant to last.
Employees23Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.